The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More
Researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding. The study focused on B-cell lymphoma 6 (BCL6), a protein implicated in several cancers. Using advanced computational techniques, the team showed how subtle changes in drug molecules can disrupt or… Read More
The first patient has been dosed in the Phase I/II clinical trial of a MTHFD1/2 inhibitor to treat advanced solid tumours, biotechnology company One-carbon Therapeutics has announced. TH9619, a first-in-class, potent, small-molecule, and a dual inhibitor of MTHFD1/2. TH9619 kills cancer cells via a dual mechanism of… Read More
News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW. This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer. The top stories: Medication detrimental to gut microbiome,… Read More
Mosaic Therapeutics has announced the appointment of Dr Stephen Shuttleworth as Chief Scientific Officer. Shuttleworth has been a Venture Partner at Samsara BioCapital, Palo Alto, US since 2019, where his responsibilities included R&D due diligence, new company creation and C-suite level company leadership. He previously served as CSO, COO and… Read More
GSK has announced a strategic collaboration with biotechnology company LTZ to advance novel myeloid cell engagers (MCEs) in oncology. The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumours. The agreement grants GSK an exclusive option to license worldwide development… Read More
US healthcare organisation ChristianaCare has launched a first-of-its-kind organoid core to personalise cancer treatment. The organoid core was unveiled at ChristianaCare’s Cawley Center for Translational Cancer Research, with a new laboratory facility in the Helen F Graham Cancer Center & Research Institute. The new facility will be used to grow… Read More
The Osteosarcoma Institute (OSI) has awarded over $1.5 million in research funding to four projects aiming to advance the treatment of osteosarcoma. The OSI, which works to increase treatment options and survival rates in osteosarcoma patients, has awarded sums between $125,000 and $500,000 to projects in the field. … Read More
Nuclear materials recycled in the UK are set to be used to develop cutting-edge cancer treatments. A new government-backed project, led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), will use a radionuclide called lead-212 to create treatments known as Targeted Alpha Therapies. The project has… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More
News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW. This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More
Biotechnology company Leucid Bio has established proof-of-concept for CAR-T therapy LEU011 for the treatment of solid tumours. LEU011 is being evaluated in the ongoing AERIAL trial, but data has established proof-of-concept by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Analysis… Read More
Research showing the Covid-19 mRNA vaccine boosts the immune system’s response to cancer has been described as ‘extraordinary’. Scientists at the University of Florida and the University of Texas MD Anderson Cancer Center found patients with advanced lung or skin cancer lived significantly longer when receiving the… Read More
DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of… Read More
Biotechnology company MaaT Pharma has announced preclinical results for its drug candidate MaaT034, including promising anti-tumour efficacy results and immune activation. MaaT034, a first-in-class co-cultured full ecosystem product, is designed to optimise intestinal microbiome functions and improve patient responses to immunotherapy in combination with Immune Checkpoint Inhibitors (ICIs). The… Read More
Researchers have discovered a ‘handbrake’ mechanism controlling how cells respond to cancer drugs, which could reshape understanding of cancer drug resistance. The breakthrough research, led by scientists from the University of Oxford and the Research Centre for Molecular Medicine, Austria, demonstrates how the enzyme NUDT5 acts as a molecular… Read More
